Anti-TNF drugs in patients with hepatitis B or C virus infection: Safety and clinical management

Expert Opinion on Biological Therapy

Volumn 12, Issue 2, 2012, Pages 193-207

  Vigan, Mauro ^a   Degasperi, Elisabetta ^b   Aghemo, Alessio ^b   Lampertico, Pietro ^b   Colombo, Massimo ^b  

^a San Giuseppe Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Adalimumab; Anti TNF ; Etanercept; Hepatitis B virus; Hepatitis C virus; Hepatitis reactivation; Infliximab

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; ETANERCEPT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATALITY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; PATIENT MONITORING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; VIRUS REACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE MANAGEMENT; DRUG TOXICITY; DRUG-INDUCED LIVER INJURY; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; PATIENT SAFETY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84855716062     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.646986     Document Type: Review

References (107)

1. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79
2. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76 (Pubitemid 44204996)
3. Schreiber S, Campieri M, Colombel JF, et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001 - 2003. Int J Colorectal Dis 2001;16:1-13
4. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34 (Suppl 1):S1-3 (Pubitemid 43197742)
5. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45 (Pubitemid 27527771)
6. Raimondo G, Allain J-P, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-657
7. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
8. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24 (Pubitemid 32927983)
9. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B infection. J Hepatol 2007;46:160-70
10. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liv Dis 2007;39:397-408 (Pubitemid 46508732)
11. Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001;7:287-94 (Pubitemid 33062093)
12. Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 2010;62:749-54
13. Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:R179
14. Chevaux JB, Nani A, Oussalah A, et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010;16:916-24
15. Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: A nationwide, multicenter study. Am J Gastroenterol 2009;104:57-63
16. Kasahara S, Ando K, Saito K, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003;77:2469-76 (Pubitemid 36222771)
17. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000;223:241-57 (Pubitemid 30337778)
18. Carroll MB, Bond ML. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008;38:208-17
19. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36 (Pubitemid 26054933)
20. Ozorio G, McGarity B, Bak H, et al. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007;187:524-6
21. Garc?a Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 2007;26:811-13 (Pubitemid 46554102)
22. Thiefin G, Morelet A, Heurgue A, et al. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 2008;15:737-9
23. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9 (Pubitemid 44133258)
24. Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005;50:163-6 (Pubitemid 40379157)
25. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007;13:1453-4 (Pubitemid 350206866)
26. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008;43:397-401 (Pubitemid 351958904)
27. Millonig G, Kern M, Ludwiczek O, et al Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006 12 974-6
28. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5 (Pubitemid 39120128)
29. Del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, et al. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004;10:701-2 (Pubitemid 39294531)
30. Wendling D, Di Martino V, Prati C, et al. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 2009;76:308-11
31. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005;64:788-9 (Pubitemid 40559316)
32. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, et al. Risk factors for opportunistic infections in infliximab-treated patients: The importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009;28:331-7
33. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35:421-4 (Pubitemid 351374414)
34. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7 (Pubitemid 36760576)
35. Sakellariou GT, Chatzigiannis I. Long-term anti-TNF therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007;26:950-2 (Pubitemid 46951296)
36. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: A retrospective record review of 11 patients. Clin Rheumatol 2009;28:787-91
37. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008;27:1069-71
38. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003;30:1624-5 (Pubitemid 36835467)
39. Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology 2009;48:450-1
40. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005;52:2519-20 (Pubitemid 41117440)
41. Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol 2010;published online 9 April 2010; doi: 1007/s10067-010-1438-y
42. Verhelst X, Orlent H, Colle I, et al. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 2010;22:494-9
43. Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009;36:2416-20
44. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718-20
45. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9 (Pubitemid 46668261)
46. Matsumoto T, Marusawa H, Dogaki M, et al. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int 2010;30:1241-2
47. Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011;46:556-64
48. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010;69:1352-5
49. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010;25:864-71
50. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9 (Pubitemid 37500439)
51. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 2008;47:844-53 (Pubitemid 351449676)
52. Katz LH, Fraser A, Gafter-Gvili A, et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008;15:89-102
53. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
54. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: A meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005
55. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006;45:1294-7 (Pubitemid 44542073)
56. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9 (Pubitemid 38067531)
57. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008;14:245-6
58. Zingarelli S, Airo P, Frassi M, et al. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo 2008;60:22-17
59. Zoulim F Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011 31 (Suppl 1) 111-16
60. Esteve M, Loras C, Gonzalez-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007;13:1450-1 (Pubitemid 350206863)
61. Conde-Taboada A, Munoz JP, Munoz LC. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol 2009;60:1077-80
62. Kuroda T, Wada Y, Kobayashi D, et al. Effect of etanercept and entecavir in a patient with rheumatoid arthritis who is a hepatitis B carrier: A review of the literature. Rheumatol Int 2010;published online 9 January 2010; doi: 10.1007/s00296-009-1344-2
63. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
64. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-73
65. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:74-81
66. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8 (Pubitemid 36799109)
67. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10 (Pubitemid 43980109)
68. Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011;54:1127-34
69. EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 2011 55 245-64
70. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73 (Pubitemid 46999083)
71. Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: A correlation with histological fibrosis and activity. J Hepatol 1999;30:185-91 (Pubitemid 29071178)
72. Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94
73. Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: A drug caught between past and future. Expert Opin Biol Ther 2011;11:301-13
74. Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-31
75. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase II randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22 (Pubitemid 40254244)
76. Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60
77. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-41 (Pubitemid 29468237)
78. Kamal SM, Fehr J, Roesler B, et al. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-83
79. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35:1944-9
80. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82 (Pubitemid 37323572)
81. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800-4 (Pubitemid 39372039)
82. Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007;26:1127-9 (Pubitemid 46863957)
83. Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006;54:2335-7 (Pubitemid 44051096)
84. Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol 2007;102:1333-4 (Pubitemid 46802003)
85. Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191-2 (Pubitemid 32158214)
86. Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003;98:504-5 (Pubitemid 36232412)
87. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006;54:361-2 (Pubitemid 43144420)
88. De Simone C, Paradisi A, Capizzi R, et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006;54:1102-4 (Pubitemid 43732395)
89. Cassano N, Vena GA. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol 2008;47:980-1
90. Alcaide AJ, Barrera MV, Habicheyn S, et al. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol 2008;22:1514-16
91. Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 2007;46:97-9 (Pubitemid 44932794)
92. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008;8:104-6
93. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003;38:511-17 (Pubitemid 36399256)
94. Ierardi E, Valle ND, Nocchiero MC, et al. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig 2006;26:673-6 (Pubitemid 44627852)
95. Soto-Fernandez S, Gonzalez-Carro P, DePedro-Esteban A, et al. Infliximab-induced hepatitis in a patient with Crohn's disease. Gastroenterol Hepatol 2006;29:320-2
96. Wahie S, Alexandroff A, Reynolds NJ. Hepatitis: A rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 2006;31:460-1
97. Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009;28:1001-3
98. Kluger N, Girard C, Guillot B, Bessis D. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis. Acta Derm Venereol 2009;89:332-4
99. Mancini S, Amorotti E, Vecchio S, et al. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010;5:193-200
100. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-6 (Pubitemid 32043002)
101. Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2001;44:1966-8 (Pubitemid 32758248)
102. Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64:1519-20 (Pubitemid 41623873)
103. Tobon GJ, Canas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26:578-81 (Pubitemid 46359303)
104. Marques M, Magro F, Cardoso H, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 2008;14:723-5 (Pubitemid 351743000)
105. Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008;27:1597-8
106. Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 2009;34:421-2
107. Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti-tumor necrosis factor-alpha (TNFalpha) use for inflammatory bowel disease. Inflamm Bowel